A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. (Q54656439)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

phase II clinical trial

0 references

0 references

peritoneal carcinoma

1 reference

based on heuristic

inferred from title

author name string

J J Biagi

1

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

A M Oza

2

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

H I Chalchal

3

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

R Grimshaw

4

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

S L Ellard

5

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

U Lee

6

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

H Hirte

7

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

J Sederias

8

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

S P Ivy

9

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

E A Eisenhauer

10

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

publication date

12 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

22

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

2

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

335-340

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Angiogenesis in epithelian ovarian cancer

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Angiogenic molecule Tie-2 and VEGF in the pathogenesis of pleural effusions

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ357

21 January 2018

Identifiers

10.1093/ANNONC/MDQ357

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20705911

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54656439&oldid=1505506954"